GlobalData: Uveitis market to grow to $1.5 billion in the seven major markets by 2033
The uveitis market in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $522.5 billion in 2023 to $1.5 billion in 2033, driven by the entry of therapies with new mechanisms of action and route of administration into the market, as well as the growth of the uveitis population, forecasts GlobalData, a leading data and analytics company.
Anticipated launch of six novel pipeline agents
GlobalData’s latest report, “Uveitis: Opportunity Assessment and Forecast,” reveals that the growth will be supported by the anticipated launch of six novel pipeline agents, two of which are projected to launch across the 7MM, coupled with the growing uveitis population throughout the forecast period.
Sara Reci, MSc, Managing Pharma Analyst at GlobalData, comments: “While the use of corticosteroids are well-established in the uveitis space, their side effects profile makes them fall short. The key opinion leaders (KOLs) interviewed by GlobalData emphasized that the most pressing unmet needs in the management of uveitis included improving the safety and side-effect profile, longer acting therapies, drugs with other mechanisms of action, and greater awareness and education of physicians.”
New mechanisms of action
Looking ahead, the late-stage pipeline products that are anticipated to reach the uveitis market during the forecast period will introduce new mechanisms of action.
These include
- Tarsier Pharma’s TRS-01, an angiotensin-converting enzyme 2 activator, neuropilin-1 antagonist, and toll like receptor family inhibitor administered as eye drops
- Priovant Therapeutics’ PF-06700841-15 (brepocitinib tosylate), a non receptor tyrosine protein kinase TYK2 inhibitor and tyrosine protein kinase JAK1 inhibitor administered orally
- Eli Lilly’s Olumiant (baricitinib), a tyrosine protein kinase JAK1 inhibitor, tyrosine protein kinase JAK2 inhibitor, administered orally
- Kiora Pharmaceuticals’ KIO-104, a dihydroorotate dehydrogenase quinone mitochondrial inhibitor, administered intravitreally
- Roche’s EBI-031 (vamikibart), an IL-6 inhibitor administered intravitreally
- Oculis Holding’s OCS-02 (licaminlimab), a TNF inhibitor in late-stage pipeline development, introduces the first monoclonal antibody with an ophthalmic route of administration into the uveitis space
Reci continues: “All in all, these late-stage pipeline candidates are of great benefit within the uveitis space, especially in the cases of patients who do not respond well to existing treatment options.”
While the uveitis market is projected to grow in the forecast period across the 7MM, it may face some challenges. KOLs have noted that despite the side effects associated with corticosteroids, they have a proven track record in being effective and quick-acting.
Reci concludes: “Pipeline agents will face difficulty in proving that their efficacy matches that of corticosteroids. Furthermore, an anticipated high cost of therapy associated with pipeline agents may impact the drugs’ shares of the market once they reach the uveitis market. Nonetheless, the launch of late-stage pipeline therapies with new mechanisms of action, routes of administration, and longer treatment intervals will undoubtedly be a driving force for market growth in the uveitis space.”
Source: GlobalData